Viatris Inc (NQ: VTRS )

11.45 -0.04 (-0.39%)
Streaming Delayed Price Updated: 2:46 PM EDT, Oct 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,431,766
Open 11.48
Bid (Size) 11.44 (56)
Ask (Size) 11.45 (26)
Prev. Close 11.49
Today's Range 11.33 - 11.52
52wk Range 8.740 - 13.62
Shares Outstanding 1,212,301,241
Dividend Yield 4.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit
How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit 
Via News Direct
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Regeneron filed an appeal after a court's decision, which was issued under seal. 
Via Benzinga

Performance

YTD
+0.48%
+0.48%
1 Month
-3.74%
-3.74%
3 Month
+9.73%
+9.73%
6 Month
-4.15%
-4.15%
1 Year
+13.88%
+13.88%

More News

Read More
EXCLUSIVE: Options Expert Warns Of 'Terrible Week' After Friday's Triple Witching
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
Via Benzinga
Peering Into Viatris's Recent Short Interest
Via Benzinga
Looking Into Viatris's Recent Short Interest
Via Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
Via Benzinga
3 Top Value Stocks to Buy Right Now
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
US Drugmaker Viatris Q2 Earnings Edge Out Analysts Expectation On Strong Demand For Branded And Generic Drugs
Via Benzinga
Why Viatris Stock Is Jumping Today
Via The Motley Fool
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
3 Surprisingly Underrated Stocks to Buy Right Now
Via The Motley Fool
Warner Bros. Discovery & Coinbase Are Among 10 Large Cap Stocks That Shined Most Last Week (July 14-July 20): Are The Others In Your Portfolio?
Via Benzinga
S&P 500 Four Under Five
Via Talk Markets
Topics Stocks
Exposures US Equities
Weak Sales From Lipitor, Norvasc Hurt Viatris' Q1 Earnings, Lowers Annual Forecast
Via Benzinga
Stocks Rebound As Rising Jobless Claims Sustain Rate-Cut Hopes, Dollar Falls, Gold Rallies: What's Driving Markets Thursday?
Via Benzinga
Topics Economy
Exposures Interest Rates
VTRS Stock Earnings: Viatris Meets EPS, Misses Revenue for Q1 2024
Via InvestorPlace
BTIG Research Predicts Over 118% Rally for These 3 Stocks
Via InvestorPlace
Steady Returns Ahead: 3 Dividend Stocks for Stable Income in Q2
Via InvestorPlace
Is Viatris a Great Dividend Stock or Just a Value Trap?
Via The Motley Fool
2 Dirt Cheap Dividend Stocks to Buy and Hold
Via The Motley Fool
Scott+Scott Attorneys at Law LLP & Hedin Hall LLP Announce Notice of Class Action and Proposed Settlement to All Who Purchased or Acquired Shares of Viatris Inc. Pursuant to a November 2020 Merger of Mylan N.V. and Upjohn, Inc. to Form Viatris
From Scott+Scott Attorneys at Law and Hedin Hall LLP
Via Business Wire
Stocks Fall Ahead Of Fed's Inflation Data, UnitedHealth Sinks, Bitcoin Tops $61,000: What's Driving Markets Wednesday?
Via Benzinga
Topics Economy
Exposures Interest Rates
Earnings Scheduled For February 28, 2024
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.